A New Treatment Landscape for RCC: Association of the Human Microbiome with Improved Outcomes in RCC.

Autor: Piao XM; Department of Urology, College of Medicine, Chungbuk National University, Cheongju 28644, Republic of Korea., Byun YJ; Department of Urology, College of Medicine, Chungbuk National University, Cheongju 28644, Republic of Korea., Zheng CM; Department of Urology, College of Medicine, Chungbuk National University, Cheongju 28644, Republic of Korea., Song SJ; Department of Emergency, Chungbuk National University Hospital, Cheongju 28644, Republic of Korea., Kang HW; Department of Urology, College of Medicine, Chungbuk National University, Cheongju 28644, Republic of Korea.; Department of Urology, Chungbuk National University Hospital, Cheongju 28644, Republic of Korea., Kim WT; Department of Urology, College of Medicine, Chungbuk National University, Cheongju 28644, Republic of Korea.; Department of Urology, Chungbuk National University Hospital, Cheongju 28644, Republic of Korea., Yun SJ; Department of Urology, College of Medicine, Chungbuk National University, Cheongju 28644, Republic of Korea.; Department of Urology, Chungbuk National University Hospital, Cheongju 28644, Republic of Korea.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2023 Feb 01; Vol. 15 (3). Date of Electronic Publication: 2023 Feb 01.
DOI: 10.3390/cancers15030935
Abstrakt: Microbes play different roles in metabolism, local or systemic inflammation, and immunity, and the human microbiome in tumor microenvironment (TME) is important for modulating the response to immunotherapy in cancer patients. Renal cell carcinoma (RCC) is an immunogenic tumor, and immunotherapy is the backbone of its treatment. Correlations between the microbiome and responsiveness to immune checkpoint inhibitors have been reported. This review summarizes the recent therapeutic strategies for RCC and the effects of TME on the systemic therapy of RCC. The current understanding and advances in microbiome research and the relationship between the microbiome and the response to immunotherapy for RCC are also discussed. Improving our understanding of the role of the microbiome in RCC treatment will facilitate the development of microbiome targeting therapies to modify the tumor microbiome and improve treatment outcomes.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje